Open Access
Subscription or Fee Access
Oncolytic Viruses (OV) Mediated Targeted Therapy to Eradicate Chronic Myeloid Leukemia (CML): A Review
Abstract
With the recent advances in scientific scenarios globally, an innovative introduction of cancer vaccines and a much safer and more effective way to eradicate cancer has been evolved. The viruses that are not severely harmful to the humans and do not recognize the human as their natural host can be deployed as an oncolytic virus to eradicate the malignancy either by killing or lysing the oncogenic cells or indirectly stimulating the immune system of the host to defend the prevailing cancerous condition of the body. The oncolytic virus-mediated immune therapy and oncolytic virotherapy are promising to remediate cancer and various malignancies all around. This review encapsulates the introduction to various oncolytic viruses, their mechanism of action, focussing on a deadly haematological and chromosomal malignancy called Chronic Myeloid Leukemia (CML), which is the consequence of the abnormal translocation and mutated fusion of the BCR-ABL1 oncogene, which in turn enhances the formation of the BCR-ABL1 tyrosine kinase. This will convert the hematopoietic cells to abnormal CML cells. CML is a cancerous disease of the bone marrow and the blood cells, especially WBC, which can be clinically eradicated by the oncolytic approach of the adenovirus cloned with the Beclin-1 gene to lyse the malignant cells or to make the cancer cells susceptible to drug-based chemotherapy by breaking the rigid resistance of the cancer cells. Although the oncolytic viruses are many, their selection is based on viral invasion, transmission, replication, as well as proliferation inside the cancer cells and the capability of cell lysis. Beyond the numerous beneficial effects, the review also sheds light on the possible adverse effects of this innovative and sophisticated approach to cancer.
Keywords
References
“What Is Chronic Myeloid Leukemia? Leukemia Types” Cancer.org. Published 2018. Accessed August 6, 2022. https://www.cancer.org/cancer/chronic-myeloid-leukemia/about/what-is cml.html
Chronic Myeloid Leukemia “Leukemia and Lymphoma Society” Lls.org. Published 2022. Accessed August 6, 2022. https://www.lls.org/leukemia/chronic-myeloid-leukemia
Sullivan, Con, et al. “Targeted therapy of chronic myeloid leukemia.” Biochemical pharmacology 80.5 (2010): 584–591.
Hantschel, Oliver, and Giulio Superti-Furga. “Regulation of the c-Abl and Bcr–Abl tyrosine kinases.” Nature reviews Molecular cell biology 5.1 (2004): 33–44.
“Chronic Myelogenous Leukemia Treatment (PDQ®)–Patient Version” National Cancer Institute. Published March 25, 2022. Accessed August 6, 2022. https://www.cancer.gov/types/leukemia/patient/cml-treatment-pdq
Sullivan, Con, et al. “Targeted therapy of chronic myeloid leukemia.” Biochemical pharmacology 80.5 (2010): 584–591.
Wodarz, Dominik. “Use of oncolytic viruses for the eradication of drug-resistant cancer cells.”Journal of The Royal Society Interface 6.31 (2009): 179–186.
Tong, Yin, et al. “Potent antitumor activity of oncolytic adenovirus expressing Beclin-1 via induction of autophagic cell death in leukemia.” Oncotarget 4.6 (2013): 860.
Qu, Xueping, et al. “Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene.” The Journal of clinical investigation 112.12 (2003): 1809–1820.
Yue, Zhenyu, et al. “Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor.” Proceedings of the National Academy of Sciences 100.25 (2003): 15077–15082.
Dalby, Kevin, et al. “Targeting the pro-death and pro-survival functions of autophagy as novel therapeutic strategies in cancer.” Autophagy 6.3 (2010): 322–329.
Ding, Zhen-Bin, et al. “Association of autophagy defect with a malignant phenotype and poor prognosis of hepatocellular carcinoma.” Cancer research 68.22 (2008): 9167–9175.
Zhou, Wei-Hua, et al. “Low expression of Beclin 1, associated with high Bcl-xL, predicts a malignant phenotype and poor prognosis of gastric cancer.” Autophagy 8.3 (2012): 389–400.
Huang, Jia-Jia, et al. “Beclin 1 expression predicts favorable clinical outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP.” Human pathology 42.10 (2011): 1459–1466.
Liang, Li‐Zhong, et al. “High expression of the autophagy gene Beclin‐1 is associated with favorable prognosis for salivary gland adenoid cystic carcinoma.” Journal of oral pathology & medicine 41.8 (2012): 621–629.
Montagnaro, Serena, et al. “Caprine herpesvirus 1 (CpHV-1) as a potential candidate for oncolytic virotherapy.” Cancer Biology & Therapy 20.1 (2019): 42–51.
Rodrigues, R., B. Cuddington, and K. Mossman. “Bovine herpesvirus type 1 as a novel oncolytic virus.” Cancer gene therapy 17.5 (2010): 344–355.
Yurchenko, Kseniya S., et al. “Oncolytic effect of wild-type Newcastle disease virus isolates in cancer cell lines in vitro and in vivo on xenograft model.” PLoS One 13.4 (2018): e0195425.
Millward, Stewart, and Angus F. Graham. “Structural studies on reovirus: discontinuities in the genome.” Proceedings of the National Academy of Sciences 65.2 (1970): 422–429.
Steyer, Andrej, et al. “High similarity of novel orthoreovirus detected in a child hospitalized with acute gastroenteritis to mammalian orthoreoviruses found in bats in Europe.” Journal of clinical microbiology 51.11 (2013): 3818–3825.
Shatkin, A.J., J.D. Sipe, and P. Loh. “Separation of ten reovirus genome segments by polyacrylamide gel electrophoresis.” Journal of Virology 2.10 (1968): 986–991.
Marcato, Paola, et al. “Ras transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent release.” Molecular therapy 15.8 (2007):1522–1530.
Errington, F., et al. “Inflammatory tumour cell killing by oncolytic reovirus for the treatment of melanoma.” Gene therapy 15.18 (2008): 1257–1270.
Rosen, L.E.O.N., et al. “Observations on a newly recognized virus (Abney) of the reovirus family.” American journal of hygiene 71.2 (1960): 258–65.
Packiriswamy, Nandakumar, et al. “Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma.” Leukemia 34.12 (2020): 3310–3322.
Kadia, Tapan M. “Release the hounds: virotherapy with immunotherapy.” Blood, The Journal of the American Society of Hematology 127.11 (2016): 1381–1383.
Maurer, Stefanie, et al. “Suicide gene-armed measles vaccine virus for the treatment of AML.”International journal of oncology 55.2 (2019): 347–358.
Hashiguchi, Takao, Katsumi Maenaka, and Yusuke Yanagi. “Measles virus hemagglutinin: structural insights into cell entry and measles vaccine.” Frontiers in microbiology 2 (2011): 247.
Hall, Kathryn, et al. “Reovirus-mediated cytotoxicity and enhancement of innate immune responses against acute myeloid leukemia.” BioResearch open access 1.1 (2012): 3–15.
Errington, Fiona, et al. “Reovirus activates human dendritic cells to promote innate antitumor immunity.” The Journal of Immunology 180.9 (2008): 6018–6026.
Andrews, Daniel M., et al. “Cross-talk between dendritic cells and natural killer cells in viral infection.” Molecular immunology 42.4 (2005): 547–555.
Innao, Vanessa, et al. “Oncolytic viruses and hematological malignancies: a new class of immunotherapy drugs.” Current Oncology 28.1 (2020): 159–183.
Kaufman, Howard L., Frederick J. Kohlhapp, and Andrew Zloza. “Oncolytic viruses: a new class of immunotherapy drugs.” Nature reviews Drug discovery 14.9 (2015): 642–662.
Davola, Maria Eugenia, and Karen Louise Mossman. “Oncolytic viruses: how “lytic” must they be for therapeutic efficacy?” Oncoimmunology 8.6 (2019): e1581528.
Ahmed, Asma, and Stephen WG Tait. “Targeting immunogenic cell death in cancer.” Molecular oncology 14.12 (2020): 2994–3006.
Ma, Jing, et al. “Characterization of virus-mediated immunogenic cancer cell death and the consequences for oncolytic virus-based immunotherapy of cancer.” Cell death & disease 11.1 (2020): 1–15.
Di, S. Somma, et al. “The Oncolytic Virus dl922-947 Triggers Immunogenic Cell Death in Mesothelioma and Reduces Xenograft Growth.” Frontiers in oncology 9 (2019): 564–564.
Shao, Xiaoyan, et al. “STAT3 contributes to oncolytic newcastle disease virus-induced immunogenic cell death in melanoma cells.” Frontiers in oncology 9 (2019): 436.
Gujar, Shashi, et al. “Antitumor benefits of antiviral immunity: an underappreciated aspect of oncolytic virotherapies.” Trends in immunology 39.3 (2018): 209–221.
Melchjorsen, Jesper. “Learning from the messengers: innate sensing of viruses and cytokine regulation of immunity-clues for treatments and vaccines.” Viruses 5.2 (2013): 470–527.
An, Yuanyuan, et al. “Oncolytic reovirus induces ovarian cancer cell apoptosis in a TLR3-dependent manner.” Virus Research 301 (2021): 198440.
Kleijn, Anne, et al. “The in vivo therapeutic efficacy of the oncolytic adenovirus Delta24-RGD is mediated by tumor-specific immunity.” PloS one 9.5 (2014): e97495.
Melcher, Alan, et al. “Thunder and lightning: immunotherapy and oncolytic viruses collide.”Molecular Therapy 19.6 (2011): 1008–1016.
Prestwich, Robin J., et al. “Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication.” Clinical cancer research 15.13 (2009): 4374–4381.
Tian, Yaomei, Daoyuan Xie, and Li Yang. “Engineering strategies to enhance oncolytic viruses in cancer immunotherapy.” Signal Transduction and Targeted Therapy 7.1 (2022): 1–21.
DOI: https://doi.org/10.37591/rrjomv.v12i2.2967
Refbacks
- There are currently no refbacks.